Triptolide, a diterpenoid isolated from the Chinese herb Tripterygium wilfordii Hook.f, has shown anti-tumor activities in a broad range of solid tumors. Here we examined its effects on leukemic cells and found that, at 100≤nM, it potently induced apoptosis in various leukemic cell lines and primary AML blasts. We then attempted to identify its mechanisms of action. Triptolide induced caspase-dependent cell death accompanied by a significant decrease in XIAP levels. Forced XIAP overexpression attenuated triptolideinduced cell death. Triptolide also decreased Mcl-1, but not Bcl-2 and Bcl-X L levels. Bcl-2 overexpression suppressed triptolide-induced apoptosis. Further, triptolide induced loss of the mitochondrial membrane potential and cytochrome C release. Caspase-9-knockout cells were resistant, while caspase-8-deficient cells were sensitive to triptolide suggesting criticality of the mitochondrial, but not the death receptor pathway for triptolide-induced apoptosis. Triptolide also enhanced cell death induced by other anti-cancer agents.
Introduction
Tripterygium wilfordii Hook.f, a member of the Celastraceae family of plants, has been used in Chinese medicine for centuries. Triptolide, a diterpenoid, was first isolated from the plant and structurally characterized in 1972 1 and has been used for the treatment of a variety of autoimmune diseases and as an immunosuppressant in patients with organ and tissue transplantations. [1] [2] [3] [4] Recently, triptolide was shown to have anti-tumor properties by suppressing the growth and inducing apoptosis of a broad range of human tumor cells. [5] [6] [7] [8] [9] Triptolide was also shown to sensitize cells to death induced by various agents, such as Apo2/Trail, TNF-α, and different chemotherapeutic agents. [10] [11] [12] However, despite the recognized potent anti-tumor activity of triptolide, our knowledge regarding its mechanism of action is yet limited. So far it is only known that triptolide blocks TNF-α mediated induction of c-IAP1 and c-IAP2, and the activation of NFκB 10,13,14 and induces caspase activation. 15, 16 Acute myeloid leukemia (AML) is an aggressive hematological malignancy. Despite major efforts during the past 30 years, limited progress has been made in the treatment of AML. The current primary treatment for AML is chemotherapy, which induces cell death mainly by apoptosis mediated by either the intrinsic mitochondrial or the extrinsic death receptor pathway, both of which lead to caspase activation and cell disintegration. The development of innovative therapies and identification of more effective drugs, therefore, remain high priorities for leukemia research. Because of its anti-tumor properties, tripotolide holds promise as a treatment for leukemia. However, other than recent reports that triptolide induced apoptosis in U937 cells by activating caspase-3 and
For personal use only. on . by guest www.bloodjournal.org From 4 downregulating XIAP 16 and that it downregulated Bcr-Abl expression and induced apoptosis in K562 cells, 17 virtually no work has been done to elucidate the activity and mechanisms of triptolide in leukemia. Through an understanding of the molecular mechanisms that mediate the proapoptotic activity of triptolide, it will be possible to better understand its anti-leukemic effects and to determine whether it is a candidate for clinical use. In addition, knowing the molecular targets of triptolide and its mechanism of action will enable us to design rational combination therapies that more efficiently eradicate leukemic cells. In the study described here, we examined the effects of triptolide on various leukemic cell lines and primary AML blasts and showed that triptolide at low nM concentrations potently induced apoptosis in various leukemic cell lines and primary AML blasts. We also investigated the mechanisms of triptolide-induced apoptosis in leukemic cells. Of note, a water-soluble derivative of the drug is in clinical trials in Europe.
Materials and Methods
Cells and cell cultures: OCI-AML3, OCI-AML3vec, OCI-AML3Bcl-2, U937, U937neo, U937XIAP, Jurkat, JurkatI2.1, KG1, HL-60, and K562 cells were cultured in RPMI 1640 medium; KBM5 cells in Iscove's modified Dulbecco's medium (Gibco-BRL, Gaithersburg, MD); and mouse embryonic fibroblasts (MEFs) and MEF-caspase-9-/-cells in α-MEM medium. All three media contained 10% heat-inactivated fetal calf serum (FCS), 2 mM L-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin. Colony-formation assay: The colony-formation assay was performed as previously described. 26 Briefly, 1 x 10 9 plated in 0.8% methylcellulose in Iscove's modified Dulbecco's medium supplemented with 10% FCS and 15 ng/mL recombinant human granulocyte-macrophage-colonystimulating factor (hGM-CSF). Triptolide was added at the initiation of cultures at concentrations of 10 to 100 nM. AML blast colonies were evaluated under a microscope on day 7 of culture in duplicate dishes. Cells from normal bone marrow were plated in 0.8% methylcellulose in Iscove's modified Dulbecco's medium, 1 unit/mL human erythropoietin (Amgen, Thousand Oaks, CA), and 50 ng/mL recombinant hGM-CSF.
Triptolide was added at concentrations of 10 to 100 nM. All cultures were analyzed after 14 days to determine the number of colony forming units: colony-forming unit granulocyte-macrophage (CFU-GM) colonies and burst-forming unit-erythroid (BFU-E) colonies.
Statistics: All experiments were carried out 3 times or more and results were expressed as the mean ± s.e., unless otherwise stated. The concentration of triptolide that induced annexin V positivity in 50% of cells was calculated using Calcusyn software (Biosoft, Ferguson, MO). The combination index (CI) was determined by the Chou-Talalay method 27 and Calcusyn software and was expressed as the average ± s.e. of the CI values obtained at the ED 50 , ED 75 , and ED 90 . A CI of <1 was considered to indicate a synergistic effect and a CI of 1 was considered to have an additive effect.
Results

Triptolide inhibits cell growth and induces cell death of various leukemic cells:
To investigate the effects of triptolide (see Figure 1A for the structure) on growth and Since triptolide induced cell death in clinically drug resistant primary AML cells, we tested the ability of triptolide to overcome drug resistance. We treated blasts from two clinically Ara-C resistant AML patients (Patients 13 and 16 in Table 1 ) with a low concentration of triptolide in combination with Ara-C for 48 hrs. These two samples were extremely resistant to Ara-C in vitro even at mM concentrations (not shown).
Interestingly, for patient 13, in the presence of 15.5 nM triptolide, the IC50 for Ara-C became 0.93 μM and for patient 16, in the presence of 47.8 nM triptolide, the IC50 was lowered to 2.87 μM suggesting the potential of triptolide in overcoming resistance to Ara-C in AML.
Five bone marrow samples from primary AML patients (Table 1) (Table 1) . At less than 30 nM triptolide, almost no colonies were recovered in any cases. However, triptolide also inhibited normal progenitor cell growth ( Figure 2B ).
Both CFU-GM and BFU-E were equally reduced. Since triptolide-induced cell death seems to be caspase dependent and XIAP is the most potent natural cellular inhibitor of caspases, we examined the effect of triptolide on XIAP protein levels. As shown in Figure 3C , XIAP protein levels were significantly decreased in triptolide-treated OCI-AML3 cells. To ensure that decrease of XIAP and activation of caspase-3 are a common mechanism of triptolide induced cell death in leukemic cells, we also analyzed XIAP and caspase-3 protein levels in triptolide treated U937 and HL-60 cells and in cells from AML samples (n=6). We found that triptolide induced decreases of XIAP protein levels and activation of caspase-3 in all cell lines and primary samples examined ( Figures 3D and 3E ).
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To elucidate the mechanism of XIAP inhibition, we analyzed the XIAP protein levels in the presence of the caspase inhibitor IDN-1965 and the proteasome inhibitor MG132 in OCI-AML3 cells treated with triptolide. It is well-known that XIAP is a caspase Figure 4B , triptolide significantly decreased the XIAP RNA level,
indicating that triptolide potently inhibits XIAP transcription.
If triptolide-induced cell death is indeed mediated through XIAP, then, logically, XIAP level will determine the extent to which triptolide induces cell death. To test this, we treated U937neo cells and U937XIAP cells with triptolide. As shown in Figure 4C , although the potent triptolide still induced significant cell death in U937XIAP cells, cell death was attenuated in the presence of XIAP overexpression.
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Mitochondrial pathway-mediated caspase activation is essential for triptolideinduced cell death: To determine which of the two apoptotic signaling pathways is essential for triptolide-induced caspase-dependent cell death, we examined the
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requirement for caspase-9, which is activated through the mitochondrial signaling pathway, and caspase-8, which is activated through the death receptor signaling pathway, for triptolide-induced cell death. MEFs deficient in caspase-9 (MEF-caspase-9-/-) 21 and
Jurkat cells deficient in caspase-8 (JurkatI2.1), 18 as well as their respective control cells, were treated with triptolide for 24 hrs. As shown in Figure 5A , 
Triptolide synergistically enhances doxorubicin-and Mylotarg-induced cell death:
Doxorubicin (Dox), an anthracycline derivative, is one of the most active anticancer agents, with a broad spectrum of activity against solid tumors and hematological malignancies. 29 Dox is a DNA-damaging agent and induces G2 cell cycle block and cell 32 It is currently used in the treatment of AML patients. 33 It induces a G2 cell cycle block and cell death in various leukemic cells 34 Figure 6C ). However, when triptolide was combined with Dox or Mylotarg, the G2 block was disrupted and cell death was greatly enhanced. This and the finding that the triptolide/Ara-C combination had minimal effects on either the S phase block induced by Ara-C or the enhanced cell death suggest that triptolide disrupts the Dox and Mylotarg induced G2 cell cycle block to promote cell death. (Table 1) were treated with triptolide plus Dox or triptolide plus Mylotarg, no synergistic effect on cell killing was observed ( Figure 6D ), probably due to the fact that AML blasts have a relatively low proliferative rate and therefore no G2 block was observed. Triptolide-induced cell death in AML patient samples was observed in both short-term in vitro cultures, as shown by annexin V staining, and long-term cultures as shown by colony-forming assays. After 24 hrs of treatment, blasts from AML patients were much more sensitive to triptolide than were CD34+ cells from normal bone marrow ( Figure   2A ). However, triptolide indistinguishably decreased clonogenic survival in AML blasts and normal bone marrow samples. Nonetheless, even though it is preferable for therapeutic agents to eliminate or reduce the colony formation of leukemic blasts and spare that of normal bone marrow progenitor cells, this cannot be the single determinant of the potential clinical applicability of a drug. In fact, Ara-C, the most commonly used chemotherapeutic agent in the treatment of AML, also shows little or no selectivity for malignant cells over normal cells in colony-forming assays 35 . It was reported that PG490-88, a water-soluble derivative of triptolide, at 0.25 mg/kg markedly decreased tumor growth and at 0.5 and 0.75 mg/kg doses caused profound tumor regression without apparent toxicities in nude mouse human tumor xenograft models. 36 A decrease in white blood cells was reported in clinical trials with triptolide or extracts of Tripterygium
wilfordii.
37,38 A phase I clinical trial with a water-soluble derivative of triptolide on solid tumors is presently ongoing in Europe.
In terms of its mechanism, triptolide was shown here to effectively inhibit XIAP expression at both the protein and RNA levels ( Figures 4A and 4B ). In addition, we found that the decrease in XIAP protein levels caused by triptolide was mediated through both, caspase degradation of XIAP protein and transcriptional inhibition of XIAP mRNA, but not through proteasome degradation ( Figures 4A and 4B ). NFκB [39] [40] [41] and both, the phosphatidylinositol-3 kinase (PI3K) and the mitogen-activated protein kinase kinase/extracellular-signal regulated kinase (MEK/ERK) pathways 24, 42, 43 have been shown to regulate XIAP expression. Since triptolide has been shown to inhibit NFκΒ, 13, 14 this finding suggests that the transcriptional downregulation of XIAP by triptolide is mediated, at least in part, through NFκB inhibition. We did not, however, detect any changes in AKT and ERK phosphorylation up to 4 hrs in OCI-AML3 and Jurkat cells treated with triptolide (data not shown). The notion that triptolide induces cell death through XIAP inhibition is further supported by the finding that forced XIAP overexpression attenuated triptolide-induced cell death ( Figure 4C ).
The inhibition of caspases by the broad-spectrum caspase inhibitor IDN-1965 blocked cell death induced by triptolide suggesting that it was caspase-dependent. On the other hand, MEFs deficient in caspase-9 were resistant to triptolide, indicating that mitochondrial pathway-mediated caspase-9 activation leading to effector caspase-3 cleavage is critical to triptolide's action. This was further supported by the finding that Mylotarg. The mechanism of this effect is not clear. It may be important to point out that triptolide also decreased levels of survivin and cdc2 (not shown). Survivin is an IAP that plays important roles in both cell proliferation and cell death 46, 47 and its expression is cell cycle-dependent with the highest level in G2M. 48 Cdc2, a cyclin B1-dependent kinase (Cdk1) is essential for the progression from the G2 phase to mitosis. 49, 50 Studies have shown that survivin is phosphorylated by cdc2-cyclin B1. Therefore, the inhibition of cyclin-dependent kinase decreases survivin levels and induces cell death. 
